Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Lowered by Zacks Research
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports. Several other research analysts also recently issued reports on the company. Guggenheim upped their price objective on Monte Rosa Therapeutics from $30.00 to $35.00 and gave […]
8 Jul 12:04 · The Markets Daily